GlassScriptPhysician profile
Jeffery D Long
NPI 1932284700
$9,658.47
in general payments reported to CMS, 2019-2025
47 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $999 · 2021: $1,243 · 2022: $1,190 · 2023: $1,293 · 2024: $1,684 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,464 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.59 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,548.83 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $993.41 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $842.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $649.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $491.77 | 2019-2025 | |
| Amgen INC. | $358.89 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $340.14 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $321.30 | 2019-2021 | |
| Corcept Therapeutics | $318.63 | 2022-2025 | Korlym |
| Lilly USA, LLC | $306.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $292.65 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.12 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $288.53 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Sunovion Pharmaceuticals INC. | $229.60 | 2019-2022 | |
| Axsome Therapeutics, INC. | $195.36 | 2023-2025 | Auvelity, Sunosi, Symbravo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.